AbCellera Biologics (HAM:8QQ) Interest Expense : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. AbCellera Biologics's interest expense for the three months ended in Mar. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. AbCellera Biologics's Operating Income for the three months ended in Mar. 2024 was € -47.49 Mil. AbCellera Biologics's Interest Expense for the three months ended in Mar. 2024 was € 0.00 Mil. GuruFocus does not calculate AbCellera Biologics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AbCellera Biologics Interest Expense Historical Data

The historical data trend for AbCellera Biologics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Interest Expense Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.19

-5.35

-4.62

-3.82

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

AbCellera Biologics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

AbCellera Biologics (HAM:8QQ) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

AbCellera Biologics's Interest Expense for the three months ended in Mar. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-47.49 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €62.63 Mil.

AbCellera Biologics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate AbCellera Biologics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. AbCellera Biologics Inc has enough cash to cover all of its debt. Its financial situation is stable.

AbCellera Biologics (HAM:8QQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (HAM:8QQ) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ABCL:USA 8QQ:Germany

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (HAM:8QQ) Headlines

No Headlines